Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Specialized R&D Materials & Reagents Supply

Active
SBIR / STTR

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract opportunity with the National Institutes of Health under the Department of Health and Human Services focuses on the supply of specialized R&D materials and reagents. The scope involves the manufacture and delivery of high-purity chemicals, custom-synthesized molecules, antibodies, and specialized lab consumables for prime contractors working on NCI SBIR R&D projects. All deliveries must include quality control certifications and Certificates of Analysis to ensure material integrity. The contract is designated as a Total Small Business Set-Aside under the SBIR/STTR mandate, requiring the provider to have fewer than 500 employees. It falls under NAICS code 325199 and was posted on July 10, 2026, with a response deadline of September 21, 2026.

General Info

NIH subcontract for R&D materials and reagents, total small business set-aside.

Agency

Department of Health and Human Services → NIHView Agency

NAICS

325199 - All Other Basic Organic Chemical ManufacturingView NAICS

Place of Performance

Not specified

Set-Aside

SBA

Documents

This scope was carved out of 75N98026R00109.

The full solicitation package (3 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment of Health and Human Services → NIH
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department of Health and Human Services → NIH
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Supplies high-purity chemicals, specialized reagents, antibodies, or custom-synthesized molecules for prime contractors on NCI SBIR R&D projects. Manufactures and delivers custom chemical compounds, biological reagents, and specialized lab consumables. Provides Certificates of Analysis (CoA) and quality control certifications. Delivers physical materials and reagents.

Similar Contracts

Same NAICS industry code

More opportunities from Department of Health and Human Services → NIH

Same awarding agency

NAICS: 541715
SBIR / STTR
Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers.
Solicitation # 75N98026R00109
The National Cancer Institute (NCI) is soliciting proposals under the SBIR Innovative Concept Phase I Award Program to develop high-risk, disruptive technologies for the prevention, diagnosis, detection, and treatment of pediatric and rare cancers. Rare cancers are defined as malignancies with a U.S. prevalence of fewer than 200,000 individuals. The program specifically targets bold, out-of-the-box ideas that address significant unmet medical needs where current standards of care have shown limited progress. Funding is intended to help small businesses generate de-risking technical data and demonstrate proof-of-concept for therapies, devices, diagnostic tools, or digital health tools. Preliminary data is not required, provided the proposal is based on a sound scientific premise. Eligible applicants must be small business concerns with fewer than 500 employees. The estimated contract value is between 300,000 and 306,500 dollars, which includes a base budget of 300,000 dollars and an optional 6,500 dollars for Technical and Business Assistance. Awards are based on a trade-off between technical merit and other considerations, with a heavy emphasis on the potential for innovation and impact, which accounts for 50 percent of the evaluation weight. Other evaluation factors include scientific rationale and approach, commercialization potential, and personnel and resources. Proposals must be submitted via the eCPS portal by 5:00 PM Eastern Daylight Time on September 21, 2026. Submissions must consist of three distinct volumes: a technical proposal, a business proposal, and human subjects and clinical trials information, along with required foreign affiliation disclosures. All research and development work must be performed within the United States. Contractors are subject to strict reporting requirements regarding foreign relationships and must adhere to NIH policies on reproducibility and the humane care of laboratory animals.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

2 months ago

DEADLINE

in 13 days
View Details
NAICS: 541714
SBIR / STTR
Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.
Solicitation # 75N98026R00109
The National Cancer Institute (NCI) is soliciting proposals under the SBIR Innovative Concept Phase I Award Program to develop high-risk, disruptive technologies for the prevention, diagnosis, detection, and treatment of pediatric and rare cancers. Rare cancers are defined as malignancies with a U.S. prevalence of fewer than 200,000 individuals. The program seeks bold, out-of-the-box ideas based on sound scientific premises to address significant unmet medical needs, and preliminary data is not required for application. The primary goal is for small businesses to generate de-risking technical data and proof-of-concept validation while exploring commercial potential and development paths. Eligible small businesses with fewer than 500 employees can apply for a base R&D budget of up to 300,000 dollars for up to 12 months, with an additional 6,500 dollars available for Technical and Business Assistance. Awards are based on a trade-off between technical merit and cost, with the highest weight placed on the potential for innovation and impact. Key deliverables may include target validation, lead candidate optimization, in vivo efficacy studies, and preliminary PK/PD studies. Proposals must be submitted via the eCPS portal by 5:00 PM Eastern Daylight Time on September 21, 2026. Strict compliance is required regarding the disclosure of foreign affiliations, adherence to NIH data management and reproducibility policies, and the protection of human subjects and vertebrate animals. Technical proposals must adhere to specific character limits for sections such as the proposed technological solution and innovation. All performance must take place within the United States, and the government retains the right to inspect work and evaluate deliverables before final payment.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

2 months ago

DEADLINE

in 13 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS